The National Institute for Health and Care Excellence (NICE) has approved zanubrutinib as a new option for treating relapsed or refractory mantle cell lymphoma in adults who have had one previous line of treatment.
Zanubrutinib is a type of targeted treatment called a BTK inhibitor. Targeted treatments are medicines that have been specially designed to attack particular proteins on lymphoma cells. BTK inhibitors target and block a protein called Bruton’s tyrosine kinase, which is important for cancer cell survival.
Zanubrutinib is a capsule that you take by mouth once or twice a day. You carry on taking it unless your lymphoma gets worse, or you develop side effects that are difficult to cope with.
The committee at NICE made their decision because research has shown that zanubrutinib works as well as the current treatment ibrutinib, and gives doctors and patients another option.
Find out more about drug development, approval and funding, or visit Lymphoma TrialsLink for the latest on clinical trials for lymphoma.